Cargando…

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder

PURPOSE/BACKGROUND: This post hoc analysis examined the time point at which clinically significant improvement in major depressive disorder (MDD) symptoms occurs with desvenlafaxine versus placebo. METHODS: Data were pooled from 9 short-term, double-blind, placebo-controlled studies in adults with M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katzman, Martin A., Nierenberg, Andrew A., Wajsbrot, Dalia B., Meier, Ellen, Prieto, Rita, Pappadopulos, Elizabeth, Mackell, Joan, Boucher, Matthieu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596832/ https://www.ncbi.nlm.nih.gov/pubmed/28817491 http://dx.doi.org/10.1097/JCP.0000000000000775

Ejemplares similares

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder
por: Atkinson, Sarah, et al.
Publicado: (2018)

Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression
por: Zilcha-Mano, Sigal, et al.
Publicado: (2021)

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder
por: Weihs, Karen L., et al.
Publicado: (2018)

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder
por: Liebowitz, Michael R, et al.
Publicado: (2013)

Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine
por: Soares, Claudio N., et al.
Publicado: (2019)

Desvenlafaxine in the treatment of major depressive disorder
por: Lourenco, Maria Teresa C, et al.
Publicado: (2009)

PS100. Open-label Desvenlafaxine as Monotherapy for Persistent Depression Disorder: A Pilot Study
por: Ravindran, Arun V., et al.
Publicado: (2016)

A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg), and zolmitriptan (2.5 mg) in the acute treatment of migraine
por: Dahlöf, Carl, et al.
Publicado: (2004)

Desvenlafaxine
por: Andrade, Chittaranjan
Publicado: (2009)

Periodontal status in chronic periodontitis depressed patients on desvenlafaxine: An observational study
por: Bhatia, Anu, et al.
Publicado: (2018)

A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
por: Ch, Saritha, et al.
Publicado: (2022)

Sumatriptan (50 and 100 mg) in repeated migraine attacks: a patient preference study
por: Zanchin, Georgio, et al.
Publicado: (2000)

Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy
por: Lieberman, Daniel Z, et al.
Publicado: (2010)

Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention
por: Gonçalves, Andre Leite, et al.
Publicado: (2016)

PS210. Effect of Desvenlafaxine on Altered Heart Rate Variability in Persistent Depressive Disorder
por: Ravindran, Arun V., et al.
Publicado: (2016)

Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine
por: Benoit, James R.A., et al.
Publicado: (2021)

Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity
por: Lyndon, Gavin J., et al.
Publicado: (2019)

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
por: Tariot, Pierre, et al.
Publicado: (2012)

Multidisciplinar treatment in postpartum depression. Coordinated attention of psychiatrist and midwife: use of desvenlafaxine while breastfeeding
por: Sánchez Rus, S.S., et al.
Publicado: (2022)

Influence of motivational placebo-related factors on the effects of exercise treatment in depressive adolescents
por: Wunram, Heidrun Lioba, et al.
Publicado: (2021)

Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial
por: Schmulson, Max J., et al.
Publicado: (2020)

Increased expression of renal TRPM6 compensates for Mg(2+) wasting during furosemide treatment
por: van Angelen, Annelies A., et al.
Publicado: (2012)

Analgesic effect of oral paracetamol 1000 mg/ibuprofen 400 mg, paracetamol 1000 mg/codeine 60 mg, paracetamol 1000 mg/ibuprofen 400 mg/codeine 60 mg, or placebo on acute postoperative pain: a single-dose, randomized, and double-blind study
por: Lyngstad, Gaute, et al.
Publicado: (2023)

The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis
por: Zheng, Jiahuan, et al.
Publicado: (2019)

Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
por: Wade, Alan G, et al.
Publicado: (2011)

Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis
por: Zeng, Chao, et al.
Publicado: (2015)

Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials
por: Wang, Junqiao, et al.
Publicado: (2022)

Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
por: Ferris, Steven H, et al.
Publicado: (2011)

Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial
por: Maity, Nabakumar, et al.
Publicado: (2014)

Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study
por: Roh, Sungwon, et al.
Publicado: (2022)

Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL
por: Casado, JL, et al.
Publicado: (2010)

Outcomes Associated with 50 mg/d and 100 mg/d Aspirin for the Prevention and Management of Cardiovascular Disease in Chinese Elderly: Single-Center Interim Analysis of a Multicenter, Prospective, Observational Study
por: Wang, Xiting, et al.
Publicado: (2022)

Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset: A Randomized Controlled Trial
por: Koga, Masatoshi, et al.
Publicado: (2020)

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Mathews, Maju, et al.
Publicado: (2015)

Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/mL Oral Solution and 50‐mg Film‐Coated Tablet
por: Otoul, Christian, et al.
Publicado: (2016)

Residual paralysis caused by 50 mg rocuronium after reversal with 4 mg/kg sugammadex: a case report
por: Uzawa, Kohji, et al.
Publicado: (2021)

A randomized, placebo- and active-controlled, multi-country, multi-center parallel group trial to evaluate the efficacy and safety of a fixed-dose combination of 400 mg ibuprofen and 100 mg caffeine compared with ibuprofen 400 mg and placebo in patients with acute lower back or neck pain
por: Predel, Hans-Georg, et al.
Publicado: (2019)

Is Nonmicronized Diosmin 600 mg as Effective as Micronized Diosmin 900 mg plus Hesperidin 100 mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study
por: Steinbruch, Marcio, et al.
Publicado: (2020)

Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM)
por: Kesavadev, Jothydev, et al.
Publicado: (2017)

Low dose Mifepristone (100 mg) for medical termination of pregnancy
por: Seth, Shikha, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_cd3ndjr3ba6pocscgovcdt4igr